Tumoren der Prostata

The World Health Organization (WHO) classification of prostate tumors is a commonly used classification system for prostate tumors. The current version was published in 2016 as part of the  WHO Classification of Tumors of the Urinary System and Male Genital Organs  and replaces the previous classification from 2004:

Classification

Epithelial tumors
Glandular neoplasms
  • acinar adenocarcinoma
    • atrophic
    • pseudohyperplastic
    • microcystic
    • foamy gland
    • mucinous
    • signet ring-like cell
    • pleomorphic giant cell
    • sarcomatoid
  • prostatic intraepithelial neoplasia – high grade
  • intraductal carcinoma
  • ductal adenocarcinoma
    • cribriform
    • papillary
    • solid
  • urothelial carcinoma
Squamous neoplasms
  • adenosquamous carcinoma
  • squamous cell carcinoma
  • basal cell carcinoma
Neuroendocrine tumors
  • adenocarcinoma with neuroendocrine differentiation
  • well-differentiated neuroendocrine tumor
  • small cell neuroendocrine carcinoma
  • large cell neuroendocrine carcinoma
Mesenchymal tumors
Haematolymphoid tumors
  • diffuse large B-cell lymphoma
  • chronic lymphocytic leukemia/small lymphocytic lymphoma
  • follicular lymphoma
  • mantle cell lymphoma
  • acute myeloid leukemia
  • B lymphoblastic leukemia/lymphoma
Miscellaneous tumors
  • cystadenoma
  • nephroblastoma
  • rhabdoid tumor
  • germ cell tumor
  • clear cell adenocarcinoma
  • melanoma
  • paraganglioma
  • neuroblastoma
Metastatic tumors
 
Tumor of the seminal vesicles
Epithelial tumors
  • adenocarcinoma
  • squamous cell carcinoma
Mixed epithelial and stromal tumors
  • cystadenoma
Mesenchymal tumors
  • leiomyoma
  • schwannoma
  • mammary-type myofibroblastoma
  • gastrointestinal stromal tumor, NOS
  • leiomyosarcoma
  • angiosarcoma
  • liposarcoma
  • solitary fibrous tumor
  • hemangiopericytoma
Miscellaneous tumors
  • choriocarcinoma
  • seminoma
  • well-differentiated neuroendocrine tumor/carcinoid tumor
  • lymphomas
  • Ewing sarcoma
Metastatic tumors

Changes from prior versions

Modifications to the Gleason grading system were incorporated into the new version among those:

  • cribriform glands and glomeruloid glands should be graded as Gleason 4
  • grading of mucinous carcinoma of the prostate should be according to the growth pattern
New entities and variants

Newly introduced entities include:

  • intraductal carcinoma

Newly introduced variants include:

  • microcystic adenocarcinoma
  • pleomorphic giant cell adenocarcinoma
  • large cell neuroendocrine carcinoma
Siehe auch:
und weiter: